FIELD: medicine.
SUBSTANCE: present invention relates to the field of medicine, namely to a method for the treatment or prevention of heart failure or treatment of ischemic-reperfusion injury of the heart, including the extracorporeal shock wave therapy of the heart and the injection of DPP-4 inhibitor or a pharmaceutical composition containing the specified inhibitor to a subject who needs it, where the specified inhibitor or composition is injected before, during and/or after the specified shock wave therapy.
EFFECT: present invention provides for the suppression of cardiomyocyte death in patients with heart attacks, and it can effectively reduce the probability of heart failure and improve the prediction in patients with heart failure or at risk of its occurrence.
20 cl, 10 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC AGENT FOR THE TREATMENT OF CARDIOMYOPATHY, PREVIOUS MYOCARDIAL INFARCTION AND CHRONIC HEART FAILURE | 2018 |
|
RU2795320C2 |
TREATING HEART FAILURE | 2020 |
|
RU2824501C2 |
TREATMENT OF HEART FAILURE IN HUMANS | 2020 |
|
RU2811365C2 |
METHOD FOR THE COMBINED TREATMENT OF CHRONIC HEART FAILURE AGAINST THE BACKGROUND OF TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2785744C1 |
TREATING A HEART ATTACK AND ISCHEMIC INJURY WITH HALOGEN COMPOUNDS | 2015 |
|
RU2728790C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING CARDIAC DISEASES | 2010 |
|
RU2595801C2 |
METHOD OF SURGICAL TREATMENT OF HEART DISEASES OF ISCHEMIC GENESIS | 2005 |
|
RU2361529C2 |
APOPTOSIS INHIBITORS AND USE THEREOF | 2011 |
|
RU2582247C2 |
CELL AND GENE METHODS FOR IMPROVEMENT OF CARDIAC FUNCTION | 2012 |
|
RU2608957C2 |
METHOD FOR TREATING MYOCARDIAL INFARCTION | 2005 |
|
RU2294206C2 |
Authors
Dates
2022-03-17—Published
2017-11-17—Filed